title: Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report.
abstract: BACKGROUND
  The purpose of pharmacovigilance (drug safety) is collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. It is meant to identify, characterize, prevent, or minimize actual or potential risks relating to medicinal products. To prevent these adverse effects and improve our practice, health professionals have a duty to report side effects to assess this risk and evaluate the benefit/risk requirements. Mitotane (Lysodren) is used for treating adrenocortical carcinoma. Currently, no side effects concerning oral and genital mucosa have been reported.
  
  
  METHODS
  This case report is about a 50 years old woman. Six months after the initiation on mitotane treatment, she developed erosive lesions located on the oral and vaginal mucosa. These drug reactions were diagnosed as erosive lichen planus by the biopsy. This lichenoid lesions were resistant to the usual treatments, mitotane being at the time not replaceable.
  
  
  CONCLUSIONS
  This case describes an unreported adverse effect of mitotane, it is - to our knowledge - the 1st description of erosive lichenoid drug reaction due to Mitotane.
authors.affiliation: aDepartment of Dental Surgery bDepartment of Endocrinology, Brest University Hospital, Brest cDepartment of Dermatology, Quimper Hospital, Quimper dDepartment of Oral Surgery, Brest University Hospital, Brest, France.
authors.forename: Arthur
authors.initials: A
authors.lastname: Schmouchkovitch
authors.forename: Héloïse
authors.initials: H
authors.lastname: Herry
authors.forename: Philippe
authors.initials: P
authors.lastname: Thuillier
authors.forename: Véronique
authors.initials: V
authors.lastname: Kerlan
authors.forename: Camille
authors.initials: C
authors.lastname: Fleuret
authors.forename: Guy
authors.initials: G
authors.lastname: Le Toux
authors.forename: Sylvie
authors.initials: S
authors.lastname: Boisramé
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D002277:Carcinoma / Q000188:drug therapy; D005260:Female; D006801:Humans; D017512:Lichenoid Eruptions / Q000139:chemically induced*; D008875:Middle Aged; D008939:Mitotane / Q000009:adverse effects*; D009059:Mouth Diseases / Q000139:chemically induced*; D014845:Vulvar Diseases / Q000139:chemically induced*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D008939:Mitotane